


Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/577,620	
			Filing Date	January 29, 2007	
			First Named Inventor	Maria Sitges Berrondo	
			Group Art Unit	1627	
			Examiner Name	Kendra D. Carter	
			Attorney Docket Number	251989	
Sheet	1	of	2	Client Reference No.	PXUS00831/2011

OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	A A	Coats et al., <i>Arch. Otolaryngol.</i> , "Human auditory nerve action potentials and brain stem evoked responses," 103: 605-615 (1977)	
	A B	Garza-Morales et al., <i>Epilepsia</i> , "Adjunctive therapy with vinpocetin in children with refractory partial epilepsy: a pilot study in Mexico," 52(Suppl. 6): 23-263 (2011)	
	A C	Husain et al., <i>Hearing Research</i> , "Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system," 151: 71-78 (2001)	
	A D	Laukli et al., <i>Audiology</i> , "Auditory brainstem responses of the cat: on- and off-responses," 24: 217-226 (1985)	
	A E	McFadden et al., <i>Hearing Research</i> , "Effects of noise on inferior colliculus evoked potentials and cochlear anatomy in young and aged chinchillas," 117: 81-96 (1998)	
	A F	McFadden et al., <i>J. Comp. Neurol.</i> , "Cu/Zn SOD deficiency potentiates hearing loss and cochlear pathology in aged 129, CD-1 mice," 413: 101-112 (1999)	
	A G	Nekrassov et al., <i>Epilepsy Res.</i> , "Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo," 60: 63-71 (2004)	
	A H	Nekrassov et al., <i>Neurosci. Lett.</i> , "Additive effects of antiepileptic drugs and pentylenetetrazole on hearing," 406: 276-280 (2006)	
	A I	Nekrassov et al., <i>Clin. Neurophysiol.</i> , "Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine," 119: 2608-2614 (2008)	
	A J	Nekrassov et al., "B235 beneficial effect of vinpocetine treatment on sensorineural hearing loss," 8 th IBRO World Congress of Neuroscience, International Brain Research Organization, Florence, Italy (2011)	
	A K	Norton et al., <i>Ear Hear.</i> , "Identification of neonatal hearing impairment: evaluation of transient evoked otoacoustic emission, distortion product otoacoustic emission, and auditory brain stem response test performance," 21(5): 508-528 (2000)	
	A L	Sitges et al., <i>Clin. Neurophysiol.</i> , "Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing," 115: 2711-2717 (2004)	
	A M	Sitges et al., <i>Neurochem. Int.</i> , "Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes," 46: 533-540 (2005)	
	A N	Sitges et al., <i>Neurochem. Int.</i> , "Single and combined effects of carbamazepine and vinpocetine on depolarization-induced changes in Na ⁺ , Ca ²⁺ , and glutamate release in hippocampal isolated nerve endings," 49: 55-61 (2006)	
	A O	Sitges et al., <i>Neuropharmacol.</i> , "Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na ⁺ channel-mediated release of [3H]Glu in hippocampal nerve endings," 52: 598-605 (2007)	
	A P	Sitges et al., <i>Clin. Neurophysiol.</i> , "Acute and chronic effects of carbamazepine, phenytoin, valproate and vinpocetine on the guinea pig BAEP parameters and threshold," 118: 420-426 (2007)	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/577,620
				Filing Date	January 29, 2007
				First Named Inventor	Maria Sitges Berrondo
				Group Art Unit	1627
				Examiner Name	Kendra D. Carter
				Attorney Docket Number	251989
Sheet	2	of	2	Client Reference No.	PXUS00831/2011

OTHER - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	A Q	Sitges et al., <i>Neuropharmacol.</i> , "Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca ²⁺ channel-mediated release of [3H]Glu: Comparison with the Na ⁺ channel-mediated release," 53: 854-862 (2007)	
	A R	Sitges et al., <i>Neurochem. Res.</i> , "Characterization of phenytoin, carbamazepine, vinpocetine and clorgyline simultaneous effects on sodium channels and catecholamine metabolism in rat striatal nerve endings," 34: 470-479 (2009)	
	A S	Sitges et al., <i>Epilepsy Res.</i> , "Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs," (2011)	
	A T	Uzuka et al., <i>J. Vet. Intern. Med.</i> , "Brainstem auditory evoked responses elicited by tone-burst stimuli in clinically normal dogs," 12: 22-25 (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.